SynthesisFrontiers in oral health2025
Oral health effects of ecstasy (MDMA) and methamphetamine: a narrative review.
Synthesis in Frontiers in oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to explore the impact of 3,4 methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, on oral health, while also drawing comparisons with methamphetamine (MA) due to their pharmacological similarities and overlapping oral manifestations. MDMA is a psychostimulant derivative of amphetamine (AM) with empathogenic and hallucinogenic properties, widely consumed, especially among young adults. Its pharmacological effects lead to both acute and long-term systemic consequences. Among its oral manifestations, xerostomia is notably prevalent and strongly associated with increased intake of sugary beverages, contributing to heightened risks of carious lesions, tooth wear and periodontal disease. Bruxism and jaw clenching, frequent during MDMA use, are implicated in temporomandibular joint dysfunction and can lead to significant tooth wear lesions. This review also discusses periodontitis prevalence, often linked to poor oral hygiene, poly-drug use, and behavioral changes. Additionally, cases of soft tissue damage and unique patterns of decay have been documented. These findings highlight the need for dental professionals to recognize oral health issues associated with MDMA, MA and polydrug use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.